MYL News and Press, Mylan N.V. From 02/19/20

Summary Only 6.5 months have gone by since we assigned a BUY rating to Teva Pharmaceutical Industries Ltd (TEVA) and the stock hasn't disappointed us. A total return of 54.1% isn't only a phenomenal return for itself, but it also significantly outperformed the performance of benchmarks s...

HERTFORDSHIRE, England and PITTSBURGH , Feb. 18, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.  (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2019 financial results, as well as its 2020 financial guidance, on Thursday, Feb. 27...

Biogen (NASDAQ: BIIB) shares surged as much as 32% on Wednesday after the company won a patent challenge to its billion-dollar multiple sclerosis (MS) drug, Tecfidera. The stock finally closed 18% higher and has since gained 1.5%. The U.S. Patent and Trademark Office's patent trial and ...

Biogen (NASDAQ: BIIB) is up 18% today as news regarding a crucial patent ruling came out in the company's favor. A U.S. appeals panels denied a patient challenge (otherwise known as an inter partes review, or IPR) for Biogen's multiple sclerosis drug Tecfidera, which was contested by a gener...

Shares of Alkermes (NASDAQ: ALKS) closed almost 11% higher in Wednesday trading on news that Biogen (NASDAQ: BIIB) had successfully defended its patent on its multiple sclerosis drug Tecfidera. That's a win for Alkermes because it developed a second-generation version of Tecfidera called...

Shares of Biogen (NASDAQ: BIIB) were soaring 17.2% as of 2:59 p.m. EST on Wednesday after rising as much as 32.4% earlier in the afternoon. The big gain came on news that the Patent Trial and Appeal Board (PTAB) ruled in favor of Biogen in a challenge by Mylan (NASDAQ: MYL) to the b...

Biogen ( BIIB +17.5% ) jumps on modestly higher volume in apparent response to or in anticipation of a favorable ruling from the USPTO's Patent Trial and Appeal Board regarding a challenge to a key patent protecting top selling MS drug Tecfidera (dimethyl fumarate). A decision was expect...

Overview On July 29, 2019, Pfizer ( PFE ) and Mylan ( MYL ) jointly announced that Pfizer’s Upjohn division would be combined with Mylan in a Reverse Morris Trust transaction. The transaction is expected to be tax-free for Pfizer shareholders, who will receive 57% of the shares of t...

The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) made a joint announcement on Monday about their plan to tackle anticompetitive practices among the major drugmakers. The agencies are trying to encourage more competition to hopefully help lower drug prices. The ...

Pfizer (NYSE: PFE) recently reported fourth-quarter earnings that missed expectations on the top and bottom line. As a result, a jumpy stock market knocked a few percentage points off the stock price. Despite missing consensus forecasts, Pfizer stock looks like a perfect fit for dividend po...